Serenity and Relief for Patients with Anxiety

The first prescription digital therapeutic designed to treat Generalized Anxiety Disorder (GAD) and Panic Disorder (PD)

reVIVETM for Generalized Anxiety Disorder and Panic Disorder

Pear Therapeutics has developed reVIVETM, a prescription digital therapeutic to be used in combination with medication for treating GAD and PD

Patient-Facing Smartphone Application + Benzodiazepine Medication

What is reVIVETM?

  • reVIVETM offers an innovative method for treating GAD, a psychiatric disease characterized by long-lasting anxiety not focused on a specific object or situation, as well as PD, a disease in which debilitating anxiety and fear can arise without reasonable cause1
  • reVIVETM utilizes a combination of assessments, dosing and therapeutic paradigms to treat anxiety conditions
  • By tailoring the prescription digital therapeutic to the pharmacokinetics of the benzodiazepine, reVIVETM may be able to enhance clinical outcomes

reVIVETM as a Prescription Digital Therapeutic for Treating GAD and PD

reVIVETM produces a significant decrease in self-assessed measures of anxiety in patients diagnosed with GAD

  • A randomized controlled trial, involving 25 GAD patients, was carried out over 8 sessions and included both relaxation and exposure techniques.
  • The following psychometric questionnaires were administered to each patient before and after treatment:
    • Beck Anxiety Inventory (BAI) – a 21-item scale measuring cognitive, behavioral and physiological symptoms of anxiety
    • Hamilton Anxiety Rating Scale (HAM-A) – a 14-item scale measuring both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety)
    • State-Trait Anxiety Inventory Form (STAI) – a 2-scale questionnaire including 20 items each that differentiates between the temporary condition of “state anxiety” (STAY-Y1) and the more general and long-standing quality of “trait anxiety” (STAY-Y2)
  • Mean scores from psychometric questionnaires significantly decreased from pre-treatment to post-treatment in BAI (26.65 to 14.50; p<0.05) and STAI (54.15 to 45.50; p<0.05). HAM-A mean scores decreased from 25.00 to 15.00 (p<0.11).

Repetto et al. Pers and Ubiq Computing. 2011.

For more information, please contact us

reVIVETM is not yet FDA-cleared or available in the United States